QUICK REFERENCE GUIDE FOR SCHOOL-BASED HEPATITIS B IMMUNIZATIONS

Manitoba Eligibility Criteria for Publicly Funded Vaccines: This vaccine has been free of charge to Grade 4 students in Manitoba since 1998 and others at high risk that meet the Manitoba Health eligibility criteria - http://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html

Trade Name / Description / Contents / Supplied
Recombivax HB
Merck Canada
Non-infectious subunit viral vaccine consisting of surface antigen (HBsAg) of hepatitis B virus produced in yeast cells. / Adjuvant:
Aluminum (as amorphous aluminum hydroxyphosphate)
Other ingredients:
Sodium chloride, sodium borate, water for injection,
Manufacturing process residuals: Each dose contains less than 1 % yeast protein and <15 µg/mL formaldehyde.
The vial stopper contains latex.
This vaccine does NOT contain thimerosal. / Recombivax HB is
supplied as a sterile, slightly opaque, white suspension for injection in a single-dose vial

Store between 2 – 8 ° C. Once vial is opened it must be used with 8 hours – (Manitoba Health memo February 2003).

Age / Dose / Schedule / Route / Needle Gauge / Length
Infants*/ children
(birth to <11 years of age)
* Infants born of HBsAg-negative mothers
**See note below for other schedules for infants of HBV-positive mothers, etc. / 0.25 mL (2.5 μg)
Preferred schedule is 0, 1 and 6 months1 / IM (deltoid)
1- 1½ ” 22-25 G
Adolescents
(11 – 19 years of age) / 0.50 mL (5.0 μg)
Preferred schedule is 0, 1 and 6 months1 / IM (deltoid)
1-  1½ ” 22-25 G

1.  The preferred schedule is 0, month 1 and month 6, with at least 4 weeks between the first and second dose, 2 months between the second and third dose and 4 months between the first and the third dose. A schedule of months 0, 1 and at least 2 is also approved, but not preferred. (Canadian Immunization Guide Evergreen Edition at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-hepb-eng.php)

**Note – Refer to the Canadian Immunization Guide Evergreen Edition for dosage recommendations for infants of HBV positive mothers; adolescents 11 yrs to 15 yrs on a 2 dose schedule; 20 yrs and older, and pre-dialysis chronic renal failure or hemodialysis patients.

Source: Product Monograph Merck Canada May 22, 2012 & Canadian Immunization Guide Evergreen Ed.

@ http://www.merck.ca/assets/en/pdf/products/RECOMBIVAX_HB-PM_E.pdf and

http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php

QUICK REFERENCE GUIDE FOR SCHOOL-BASED MENINGOCOCCAL CONJUGATE C IMMUNIZATIONS

Manitoba Eligibility Criteria for Publicly Funded Vaccines: This vaccine has been free of charge to Grade 4 students in Manitoba since 2004, and was added to the routine immunization schedule at age 12 months in 1999*. Contacts of meningococcal C disease are also eligible.

Trade Name / Description / Contents / Supplied
NeisVac-C® Vaccine:
GlaxoSmithKline
Composed of a meningococcal group C polysaccharide conjugated to a tetanus toxoid protein, a chemically detoxified form of tetanus toxin, and adsorbed onto aluminum hydroxide. / Active Ingredients:
Neisseria meningitidis group C polysaccharide 10 mcg
& tetanus toxoid protein 10-20 mcg
Adjuvant: aluminum hydroxide,
Other ingredients: sodium chloride, water for injection
This vaccine does NOT contain thimerosal.
The pre-filled syringe has rubber in the cap and plunger stopper. / NeisVac-C® is supplied as a semi opaque white to off white suspension.
In a single dose 0.5 mL pre-filled syringe

Store between 2 – 8 ° C After storage a white deposit and clear supernatant can be seen. Vaccine should be well shaken to achieve a homogenous suspension. Inspect for foreign particulate matter

Age / Dose / Schedule / Route / Needles Gauge / Length
Children from 12 months to adults
*Refer to the CIG for the schedule for infants <12 months of age / Children 12 months of age and older, adolescents and adults: one 0.5 mL dose. / IM (deltoid)
1- 1 ½ ” 22-25 G

*All Grade 4 children are eligible for a dose of Men-C-C. If a child has previously received a Men-C-C vaccine, an additional dose may be offered if the time interval between doses is greater than eight (8) weeks.

·  Parents can choose to delay the Grade 4 Men-C-C dose (if their child has already had a dose) until Grade 6, to be more consistent with the NACI statement, and this dose would also be covered by Manitoba Health. The parent would need to contact a health care provider to arrange for the administration of this dose.

·  http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-meni-eng.php

Source: Product Monograph GlaxoSmithKline June 21, 2010 @ http://www.gsk.ca/english/index.html#

June 2014